|
Novartis receives European Commission approval for Gilenya®
|
21 March 2011 |
|
Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquake victims
|
17 March 2011 |
|
Novartis gains positive CHMP opinion for Rasilamlo(TM)
|
21 February 2011 |
|
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET
|
09 February 2011 |
|
Innovation drives Novartis to double-digit growth for 2010
|
30 January 2011 |
|
Sandoz announces phase II clinical trial for biosimilar version of rituximab
|
13 January 2011 |
|
European Commission approves Tasigna® for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
|
02 January 2011 |
|
Commitment of Novartis in advancing treatments for patients with cancer and rare diseases
|
02 December 2010 |
|
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
|
18 November 2010 |
|
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate
|
04 November 2010 |